Orchid granted Certificate of Suitability for Cefadroxil Monohydrate
30 Mar 2004
Chennai: Orchid Chemicals & Pharmaceuticals Ltd. (Orchid), the Chennai-based pharma major today announced that it has been granted the Certificate of Suitability (CoS) by the European Directorate for the Quality of Medicines (EDQM) for its API product Cefadroxil Monohydrate. This is the 7th CoS that has been granted to Orchid.
"Europe is a key market in our overall regulated market strategy. We are focusing on a basket of products including premium high-value products as well as established ones. We now have 7 Certificates of Suitability (CoS) granted and we are confident of enlarging our business base in Europe during the coming quarters", said Mr K Raghavendra Rao, Managing Director, Orchid Chemicals & Pharmaceuticals Ltd.
Latest articles
Featured articles
India’s ‘AI impact’ expo: Beyond the hype to industrial scale
By Cygnus | 20 Apr 2026
India AI Impact Expo 2026 highlights the shift to industrial-scale AI. Explore frugal intelligence, AI by Her startups, and India’s strategy for global AI deployment.
Post-splashdown: What Artemis II taught us about the ‘deep space wall’
By Axel Miller | 15 Apr 2026
Artemis II splashdown marks a breakthrough in deep space exploration. Discover AVATAR radiation data, Orion’s distance record, and insights shaping NASA’s 2028 Moon mission.
Can aviation go green? The multi-billion dollar race for sustainable fuel
By Cygnus | 10 Apr 2026
Airlines are racing to adopt sustainable aviation fuel, but limited supply and high costs challenge the future of green aviation.
The battery race: who will control the future of electric vehicles?
By Axel Miller | 08 Apr 2026
The global battery race is reshaping the electric vehicle industry, with China, the US, and Europe competing for control over supply chains and technology.
AI vs governments: Who controls the future of intelligence?
By Cygnus | 07 Apr 2026
Governments and AI companies like OpenAI and Anthropic are shaping the future of intelligence amid rising policy conflicts and global competition.
Strait of Hormuz: how one chokepoint controls the global economy
By Axel Miller | 06 Apr 2026
The Strait of Hormuz is a critical global chokepoint. Learn how disruptions impact oil prices, shipping, and the global economy.
The $2 trillion AI infrastructure race: Who will control global compute?
By Cygnus | 06 Apr 2026
AI spending is set to exceed $2 trillion in 2026, driving a global race in data centers, chips, and energy infrastructure.
.webp)
Artemis II and the economic outlook for lunar infrastructure
By Axel Miller | 01 Apr 2026
Artemis II will test deep-space systems and support future lunar missions, shaping the next phase of the global space economy.
Synthetic diplomacy: The $50 billion mirage and the new era of market-moving deepfakes
By Cygnus | 30 Mar 2026
Synthetic diplomacy shows how deepfakes could trigger market volatility, highlighting the growing need for verification in global financial systems.
Latest articles
